Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 861

1.

Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.

Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.

Am J Obstet Gynecol. 2004 Dec;191(6):1979-88.

PMID:
15592280
[PubMed - indexed for MEDLINE]
2.

Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.

Palacios S, Farias ML, Luebbert H, Gomez G, Yabur JA, Quail DC, Turbi C, Kayath MJ, Almeida MJ, Mönnig E, Nickelsen T.

Am J Obstet Gynecol. 2004 Jul;191(1):121-31.

PMID:
15295352
[PubMed - indexed for MEDLINE]
3.

Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.

Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L Jr.

Obstet Gynecol. 2004 Feb;103(2):267-73.

PMID:
14754694
[PubMed - indexed for MEDLINE]
4.

Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women.

Morgante G, Farina M, Cianci A, La Marca A, Petraglia F, De Leo V.

Gynecol Endocrinol. 2004 Apr;18(4):194-8.

PMID:
15293890
[PubMed - indexed for MEDLINE]
5.
6.

Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.

Valiati B, Capp E, Edelweiss MI, de Freitas FM, Wender MC.

Maturitas. 2009 Jan 20;62(1):81-4. doi: 10.1016/j.maturitas.2008.10.013. Epub 2008 Dec 20.

PMID:
19097715
[PubMed - indexed for MEDLINE]
7.

Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.

Davis SR, O'Neill SM, Eden J, Baber R, Ekangaki A, Stocks JM, Thiebaud D.

Menopause. 2004 Mar-Apr;11(2):167-75.

PMID:
15021446
[PubMed - indexed for MEDLINE]
8.

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.

Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR; Women's Health Initiative Investigators.

Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73.

PMID:
15863546
[PubMed - indexed for MEDLINE]
9.

Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study.

D'Anna R, Cannata ML, Atteritano M, Cancellieri F, Corrado F, Baviera G, Triolo O, Antico F, Gaudio A, Frisina N, Bitto A, Polito F, Minutoli L, Altavilla D, Marini H, Squadrito F.

Menopause. 2007 Jul-Aug;14(4):648-55.

PMID:
17251874
[PubMed - indexed for MEDLINE]
10.

Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.

Bachmann G, Crosby U, Feldman RA, Ronkin S, Constantine GD.

Menopause. 2011 May;18(5):508-14. doi: 10.1097/gme.0b013e3181fa358b.

PMID:
21289525
[PubMed - indexed for MEDLINE]
11.

Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study.

D'Anna R, Cannata ML, Marini H, Atteritano M, Cancellieri F, Corrado F, Triolo O, Rizzo P, Russo S, Gaudio A, Frisina N, Bitto A, Polito F, Minutoli L, Altavilla D, Adamo EB, Squadrito F.

Menopause. 2009 Mar-Apr;16(2):301-6. doi: 10.1097/gme.0b013e318186d7e2.

PMID:
19034051
[PubMed - indexed for MEDLINE]
12.

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.

Stovall DW, Utian WH, Gass ML, Qu Y, Muram D, Wong M, Plouffe L Jr.

Menopause. 2007 May-Jun;14(3 Pt 1):510-7.

PMID:
17314736
[PubMed - indexed for MEDLINE]
13.

Persistent hot flushes in older postmenopausal women.

Huang AJ, Grady D, Jacoby VL, Blackwell TL, Bauer DC, Sawaya GF.

Arch Intern Med. 2008 Apr 28;168(8):840-6. doi: 10.1001/archinte.168.8.840.

PMID:
18443259
[PubMed - indexed for MEDLINE]
14.

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.

Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR.

J Clin Oncol. 2001 Jun 15;19(12):3111-6. Erratum in: J Clin Oncol 2002 Mar 1;20(5):1430.

PMID:
11408508
[PubMed - indexed for MEDLINE]
15.

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F.

Am J Obstet Gynecol. 2001 Feb;184(3):350-3.

PMID:
11228485
[PubMed - indexed for MEDLINE]
16.

Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.

Bachmann GA, Schaefers M, Uddin A, Utian WH.

Obstet Gynecol. 2007 Oct;110(4):771-9.

PMID:
17906008
[PubMed - indexed for MEDLINE]
17.

Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis.

Modugno F, Ness RB, Ewing S, Cauley JA.

Obstet Gynecol. 2003 Feb;101(2):353-61.

PMID:
12576261
[PubMed - indexed for MEDLINE]
18.

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H 3rd, Gennari C, Christiansen C, Arnaud CD, Delmas PD.

Arch Intern Med. 2000 Dec 11-25;160(22):3444-50.

PMID:
11112238
[PubMed - indexed for MEDLINE]
19.
20.

Clinical efficacy of raloxifene in postmenopausal women.

Agnusdei D.

Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):43-6. Review.

PMID:
10428320
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk